INVEX Therapeutics Ltd (IXC)
20mins delayed
Movement
1 Year Return
INVEX Therapeutics Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $22.81 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
IXC Statistics
31 March
1,230 / 2,259
ASX Size Rank
1yr Return
vs Sector (1yr)
-66.51%
vs ASX 200 (1yr)
-13.75%
$22.81 million
Market Cap
Share Issue
31.25 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
31 March
N/A
PE Ratio
EPS ($)
-0.02
Earnings Yield
-2.77%
NTA ($)
0.19
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Invex Therapeutics Ltd (IXC) is a biopharmaceutical company, focused on the research and development of Exenatide as an efficacious treatment for neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke, hydrocephalus, venous sinus thrombosis, brain tumours, meningitis, secondary pseudo tumour cerebri and traumatic brain injury.
Upcoming Calendar
| 26 Aug 2020 | Report (Prelim) |
| 26 Aug 2020 | Report (Annual) |
| 25 Feb 2021 | Report (Interim) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
IXC is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr David McAuliffe | Non-Executive Director | Mar 2019 |
|
| Ms Narelle Warren | Company Secretary, Non-Executive Director | Mar 2019 |
|
| Dr Jason Loveridge | Non-Executive Chairman, Non-Executive Director | Mar 2019 |
|
| Dr Alexandra J Sinclair | Chief Scientific Officer, Executive Director | Jun 2019 |
|
Director Transactions
IXC directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 22/11/19 | David McAuliffe | Issued | 200,000 | $0.710 | $142,000 | Issue of options. |
| 22/11/19 | Narelle Warren | Issued | 400,000 | $0.710 | $284,000 | Issue of options. |
| 22/11/19 | Jason Loveridge | Issued | 800,000 | $0.710 | $568,000 | Issue of options. |
| 22/11/19 | Alexandra Sinclair | Issued | 800,000 | $0.710 | $568,000 | Issue of options. |
Shareholder Distribution
Shareholder Distribution data is unavailable.
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Minderoo Group Pty Ltd | 5,000,000 | 9.09% |
| JK Nominees Pty Ltd |
4,000,000 | 7.27% |
| Tisia Nominees Pty Ltd |
4,000,000 | 7.27% |
| Warambi Sarl | 3,540,000 | 6.44% |
| Mr David Jerimiah Mcauliffe |
3,225,001 | 5.86% |
| Oaktone Nominees Pty Ltd |
3,225,000 | 5.86% |
| Alexandra Jean Sinclair | 2,500,000 | 4.55% |
| The University of Birmingham | 2,000,000 | 3.64% |
| Dr Jason Loveridge | 1,566,000 | 2.85% |
| Sunset Capital Management Pty Ltd |
1,250,000 | 2.27% |
| Cityscape Asset Pty Ltd |
1,250,000 | 2.27% |
| Bannaby Investments Pty Limited |
1,250,000 | 2.27% |
| Cabletime Pty Ltd |
790,000 | 1.44% |
| Denlin Nominees Pty Ltd | 775,000 | 1.41% |
| Webinvest Pty Ltd |
625,000 | 1.14% |
| Ms Sophie Alice Loveridge | 523,000 | 0.95% |
| Ms Alexandra Loveridge | 523,000 | 0.95% |
| Ms Kathryan Mary Salkilld | 523,000 | 0.95% |
| Peter Kyros Pty Ltd |
500,000 | 0.91% |
| Alba Capital Pty Ltd | 500,000 | 0.91% |
| Magaurite Pty Ltd |
500,000 | 0.91% |
| Invia Custodian Pty Limited |
500,000 | 0.91% |
| Godney Pty Ltd |
500,000 | 0.91% |
| John Dahlsen Superannuation Fund Pty Ltd | 500,000 | 0.91% |
| Blu Bone Pty Ltd |
487,500 | 0.89% |
| Mimo Strategies Pty Ltd |
350,000 | 0.64% |
| Ardroy Securities Pty Ltd |
350,000 | 0.64% |
| Hammerhead Holdings Pty Ltd |
257,500 | 0.47% |
| Cossack Holdings (Aus) Pty Ltd |
250,000 | 0.45% |
| Mr Mark John Bahen & Mrs Margaret Patrica Bahen |
250,000 | 0.45% |
| Mr Mark John Bahen & Mrs Margaret Patrica Bahen |
250,000 | 0.45% |
| Mr Peter James Nixon | 250,000 | 0.45% |
| Dr Peter John Stow & Mrs Karen Dorothy Stow |
250,000 | 0.45% |
| Mr Andrew Murray Gregor | 250,000 | 0.45% |
| Tets Pty Ltd | 250,000 | 0.45% |
| Mr Anthony Duncan Mcintosh | 250,000 | 0.45% |
| Giokir Pty Ltd | 250,000 | 0.45% |
| Mr Alexander Stevenson Gregg & Mrs Tania Pauline Davies Gregg |
200,000 | 0.36% |
| Philuchna Pty Ltd |
200,000 | 0.36% |
| Ms Katharine Leigh Sands | 187,500 | 0.34% |
| Miss Joyce Gladys Francis | 187,500 | 0.34% |
| All other shareholders | 19.97 % | |
The Top 20 Shareholders of IXC hold 80.03% of shares on issue.
IXC Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
IXC Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Biopharmaceuticals.
Incorporated: --
Level 1, 38 Rowland St
Subiaco WA 6008
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.